Patent SG-11201810827V-A (SG)
Title: Direct reprogramming of a human somatic cell to a selected (predetermined) differentiated cell with functionalized nanoparticles
Inventor: APRIKYAN ANDRANIK ANDREW
IPC: A61K47/66
Filed: 2017-06-02
Abstract: ccO N O C () INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 07 December 2017 (07.12.2017) WIP0 I PCT omit VIII Hot o III OH olo Immo iflo oimIE (10) International Publication Number WO 2017/210638 Al (51) International Patent Classification: A61K 31/7052 (2006.01) A61K 47/55 (2017.01) A61K 31/7105 (2006.01) A61K 47/66 (2017.01) A61K 38/02 (2006.01) (21) International Application Number: PCT/US2017/035823 (22) International Filing Date: 02 June 2017 (02.06.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/345,360 03 June 2016 (03.06.2016) US (71) Applicant: STEMGENICS, INC. [US/US]; 454 N. 34th Street, Seattle, WA 98103 (US). (72) Inventor: APRIKYAN, Andranik Andrew; 454 N. 34th Street, Seattle, WA 98103 (US). (74) Agent: NOWAK, Thomas S.; Christensen O'Connor John- son Kindness PLLC, 1201 Third Avenue, Suite 3600, Seat- tle, WA 98101 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) of inventorship (Rule 4.17(iv)) Published: — with international search report (Art. 21(3)) (54) Title: DIRECT REPROGRAMMING OF A HUMAN SOMATIC CELL TO A SELECTED (PREDETERMINED) DIFFEREN- TIATED CELL WITH FUNCTIONALIZED NANOPARTICLES (57) : This disclosure relates to compositions and methods for reprogramming an initial cell (e.g., somatic cell) to generate specialized cell types of interest, such as cardiac, hepatic, blood, neuronal and other cells from human somatic cells. In some embod- iments, initial (e.g., somatic) cell is a human cell thus producing human induced cell types of interest. In some embodiments, the compositions and methods incorporate nanoparticles functionalized with biologically active molecules (RNAs, proteins, peptides and other small molecules). These newly generated (i.e., \"induced\") specialized cells are useful to improve organ function and/or tissue regeneration (heart, liver, etc.) and to screen drugs for functional activity.